Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | ACACB | O00763 | 2/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21838591 | 0.88 | NOTUM (0.57) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL22499991 | 0.86 | NOTUM (0.63) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL22499989 | 0.86 | NOTUM (0.63) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL21838630 | 0.83 | NOTUM (0.53) | NOTUMPOLBACACBSLC6A9SERPINE1 | |
| SCHEMBL1337159 | 0.79 | CACNA1B (0.51) | NOTUMPOLBACACBSLC6A9LMNA | |
| SCHEMBL25170450 | 0.76 | NOTUM (1.00) | NOTUMPOLBSERPINE1 | |
| SCHEMBL29957216 | 0.76 | NOTUM (1.00) | NOTUMPOLBSERPINE1 | |
| SCHEMBL20063904 | 0.75 | NOTUM (0.57) | NOTUMPOLBDPP4ACACBALDH1A1 | |
| SCHEMBL21838600 | 0.74 | HTR2C (0.41) | — | |
| SCHEMBL21838543 | 0.74 | HTR2C (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | NOTUM 3035/4885POLB 4679/4885DPP4 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.